Early administration of dapagliflozin preserves pancreatic β-cell mass through a legacy effect in a mouse model of type 2 diabetes

Journal of Diabetes Investigation

Volumn 10, Issue 3, 2019, Pages 577-590

  Kanno, Ayumi ^a   Asahara, Shun ichiro ^a   Kawamura, Mao ^b   Furubayashi, Ayuko ^b   Tsuchiya, Shoko ^b   Suzuki, Emi ^a   Takai, Tomoko ^a   Koyanagi Kimura, Maki ^a   Matsuda, Tomokazu ^a   Okada, Yuko ^a   Ogawa, Wataru ^a   Kido, Yoshiaki ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY   (Japan)

Author keywords

Pancreatic cell; Sodium glucose cotransporter 2; Type 2 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; INSULIN; TREFOIL FACTOR 2; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; GLUCOSIDE;

AGR2 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EARLY INTERVENTION; GENE; GENE EXPRESSION; GKN3 GENE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; MICROARRAY ANALYSIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TFF2 GENE; TIME TO TREATMENT; TREATMENT DURATION; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY; PHARMACOLOGY;

ANIMALS; BENZHYDRYL COMPOUNDS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLUCOSIDES; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85056147530     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12945     Document Type: Article

References (34)

1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2178.
2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.
3. Fioretto P, Stefansson BV, Johnsson E, et al. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 2016; 59: 2036–2039.
4. Shiba K, Tsuchiya K, Komiya C, et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep 2017; 8: 2362.
5. Okauchi S, Shimoda M, Obata A, et al. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice. Biochem Biophys Res Commun 2016; 470: 772–782.
6. Hashimoto N, Kido Y, Uchida T, et al. Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet 2006; 38: 589–593.
7. Shigeyama Y, Kobayashi T, Kido Y, et al. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol 2008; 28: 2971–2979.
8. Asahara S, Etoh H, Inoue H, et al. Paternal allelic mutation at the Kcnq1 locus reduces pancreatic β-cell mass by epigenetic modification of Cdkn1c. Proc Natl Acad Sci USA 2015; 112: 8332–8337.
9. Shimizu S, Hosooka T, Matsuda T, et al. DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPβ transgenic mice. J Mol Endocrinol 2012; 49: 125–135.
10. Matsuda T, Takahashi H, Mieda Y, et al. Regulation of pancreatic β cell mass by cross-interaction between CCAAT enhancer binding protein β induced by endoplasmic reticulum stress and AMP-activated protein kinase activity. PLoS One 2015; 10: e0130757.
11. Shimo N, Matsuoka TA, Miyatsuka T, et al. Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions. Biochem Biophys Res Commun 2015; 467: 948–954.
12. Macdonald FR, Peel JE, Jones HB, et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 2010; 12: 1004–1012.
13. Asahara S, Shibutani Y, Teruyama K, et al. Ras-related C3 botulinum toxin substrate 1 (RAC1) regulates glucose-stimulated insulin secretion via modulation of F-actin. Diabetologia 2013; 56: 1088–1097.
14. Bartolomé A, Kimura-Koyanagi M, Asahara S, et al. Pancreatic β-cell failure mediated by mTORC1 hyperactivity and autophagic impairment. Diabetes 2014; 63: 2996–3008.
15. Kawada Y, Asahara S, Sugiura Y, et al. Histone deacetylase regulates insulin signaling via two pathways in pancreatic β cells. PLoS One 2017; 12: e0184435.
16. Kitamura T, Kido Y, Nef S, et al. Preserved pancreatic beta-cell development and function in mice lacking the insulin receptor-related receptor. Mol Cell Biol 2001; 21: 5624–5630.
17. Asahara S, Matsuda T, Kido Y, et al. Increased ribosomal biogenesis induces pancreatic beta cell failure in mice model of type 2 diabetes. Biochem Biophys Res Commun 2009; 381: 367–371.
18. Zhao F, Edwards R, Dizon D, et al. Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2-/- mice. Dev Biol 2010; 338: 270–279.
19. Higa A, Mulot A, Delom F, et al. Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis. J Biol Chem 2011; 286: 44855–44868.
20. Orime K, Shirakawa J, Togashi Y, et al. Trefoil factor 2 promotes cell proliferation in pancreatic β-cells through CXCR-4-mediated ERK1/2 phosphorylation. Endocrinology 2013; 154: 54–64.
21. Menheniott TR, Peterson AJ, O'Connor L, et al. A novel gastrokine, Gkn3, marks gastric atrophy and shows evidence of adaptive gene loss in humans. Gastroenterology 2010; 138: 1823–1835.
22. Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J Clin Endocrinol Metab 2015; 100: 1927–1932.
23. Takahashi K, Nakamura A, Miyoshi H, et al. Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. Sci Rep 2018; 8: 6864.
24. Talchai C, Xuan S, Lin HV, et al. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 2012; 150: 1223–1234.
25. Kim-Muller JY, Fan J, Kim YJ, et al. Aldehyde dehydrogenase 1a3 defines a subset of failing pancreatic β cells in diabetic mice. Nat Commun 2016; 7: 12631.
26. Park JH, Stoffers DA, Nicholls RD, et al. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest 2008; 118: 2316–2324.
27. Yoshida Y, Fuchita M, Kimura-Koyanagi M, et al. Contribution of insulin signaling to the regulation of pancreatic beta-cell mass during the catch-up growth period in a low birth weight mouse model. Diabetol Int 2014; 5: 43–52.
28. Thompson RF, Fazzari MJ, Niu H, et al. Experimental intrauterine growth restriction induces alterations in DNA methylation and gene expression in pancreatic islets of rats. J Biol Chem 2010; 285: 15111–15118.
29. Matsuda T, Kido Y, Asahara S, et al. Ablation of C/EBPbeta alleviates ER stress and pancreatic beta cell failure through the GRP78 chaperone in mice. J Clin Invest 2010; 120: 115–126.
30. Oyadomari S, Koizumi A, Takeda K, et al. Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest 2002; 109: 525–532.
31. Tomasetto C, Rio MC, Gautier C, et al. hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma. EMBO J 1990; 9: 407–414.
32. Tu S, Chi AL, Lim S, et al. Gastrin regulates the TFF2 promoter through gastrin-responsive cis-acting elements and multiple signaling pathways. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1726–G1737.
33. Mukherjee S, Sengupta N, Chaudhuri A, et al. PLVAP and GKN3 are two critical host cell receptors which facilitate Japanese encephalitis virus entry into neurons. Sci Rep 2018; 8: 11784.
34. Westley BR, Griffin SM, May FE. Interaction between TFF1, a gastric tumor suppressor trefoil protein, and TFIZ1, a brichos domain-containing protein with homology to SP-C. Biochemistry 2005; 44: 7967–7975.